Rising Tax Burdens for Those Earning the Most

Rising Tax Burdens for Those Earning the Most

Is the tax code sufficiently progressive? The answer depends not only on the values of the person answering the question, but it also is a surprisingly tricky empirical exercise. What counts as income and who pays the corporate tax? How should one measure households?

Hey World: Do Not Ban E-Cigarettes

Hey World: Do Not Ban E-Cigarettes

There is a hot debate in many countries over youth use of e-cigarettes, electronic devices that deliver nicotine to consumers without the deadly tar found in the smoke from traditional cigarettes. Although nicotine is not a carcinogen, it is still bad for developing brains and should not be used by young adults or pregnant women. At the same time, e-cigarettes offer real advantages over traditional tobacco products for smokers who are otherwise unable to quit.

The Economics of Biologic Drugs

The Economics of Biologic Drugs

The market for biologic drugs in the United States is large and growing. Total US biologic sales in 2018 is estimated to have been $125 billion, an increase of 50 percent since 2014.

Biologics are Not Natural Monopolies

Biologics are Not Natural Monopolies

Recently, several physicians and health policy analysts took to the Health Affairs blog to propose what was, to anyone who has been following biosimilars for the last decade or more, a surprising and concerning idea: that biosimilars should be abandoned.

2018 Charitable Giving Dips, as Predicted

2018 Charitable Giving Dips, as Predicted

A Giving USA report released last week shows that US households’ charitable donations in 2018 experienced the largest decline since the Great Recession. We hate to say we told you so, but we told you so.